BetterLife Pharma Appoints Corporate Advisor
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) has appointed André Beaudry as Corporate Advisor. Beaudry brings over 30 years of experience in fundraising, government relations, and international program management, having secured over $140M for various initiatives including mental health across multiple countries.
As Founder of Velocity Collaboration , Beaudry is also a shareholder of BetterLife and will focus on advancing BETR-001, the company's patented non-hallucinogenic compound. The drug has completed most FDA required IND-enabling studies and aims to treat anxiety, depression, PTSD, addiction, chronic migraine, and cluster headaches by renewing neural circuits affected by chronic stress or trauma.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) ha nominato André Beaudry come Consulente Aziendale. Beaudry porta con sé oltre 30 anni di esperienza nella raccolta fondi, nelle relazioni governative e nella gestione di programmi internazionali, avendo assicurato oltre 140 milioni di dollari per varie iniziative, inclusa la salute mentale in diversi paesi.
In qualità di Fondatore di Velocity Collaboration, Beaudry è anche azionista di BetterLife e si concentrerà sull'avanzamento di BETR-001, il composto brevettato non allucinogeno dell'azienda. Il farmaco ha completato la maggior parte degli studi richiesti dalla FDA per l'IND e mira a trattare ansia, depressione, PTSD, dipendenza, emicrania cronica e mal di testa a grappolo rinnovando i circuiti neurali colpiti da stress cronico o trauma.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) ha nombrado a André Beaudry como Asesor Corporativo. Beaudry aporta más de 30 años de experiencia en recaudación de fondos, relaciones gubernamentales y gestión de programas internacionales, habiendo asegurado más de 140 millones de dólares para diversas iniciativas, incluida la salud mental en varios países.
Como Fundador de Velocity Collaboration, Beaudry también es accionista de BetterLife y se centrará en avanzar en BETR-001, el compuesto no alucinógeno patentado de la empresa. El fármaco ha completado la mayoría de los estudios requeridos por la FDA para la IND y tiene como objetivo tratar la ansiedad, la depresión, el PTSD, la adicción, la migraña crónica y los dolores de cabeza en racimo renovando los circuitos neuronales afectados por el estrés crónico o el trauma.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF)는 André Beaudry를 기업 고문으로 임명했습니다. Beaudry는 30년 이상의 자금 조달, 정부 관계 및 국제 프로그램 관리 경험을 가지고 있으며, 여러 국가에서 정신 건강을 포함한 다양한 이니셔티브에 대해 1억 4천만 달러 이상을 확보했습니다.
Velocity Collaboration의 창립자로서 Beaudry는 BetterLife의 주주이기도 하며, 회사의 특허받은 비환각 화합물인 BETR-001의 발전에 집중할 것입니다. 이 약물은 FDA가 요구하는 IND 승인 연구의 대부분을 완료했으며, 만성 스트레스 또는 외상으로 영향을 받은 신경 회로를 재생하여 불안, 우울증, PTSD, 중독, 만성 편두통 및 군발 두통을 치료하는 것을 목표로 합니다.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) a nommé André Beaudry en tant que conseiller d'entreprise. Beaudry apporte plus de 30 ans d'expérience en collecte de fonds, en relations gouvernementales et en gestion de programmes internationaux, ayant sécurisé plus de 140 millions de dollars pour diverses initiatives, y compris la santé mentale dans plusieurs pays.
En tant que fondateur de Velocity Collaboration, Beaudry est également actionnaire de BetterLife et se concentrera sur l'avancement de BETR-001, le composé non hallucinogène breveté de l'entreprise. Le médicament a complété la plupart des études requises par la FDA pour l'IND et vise à traiter l'anxiété, la dépression, le PTSD, la dépendance, la migraine chronique et les céphalées en grappes en renouvelant les circuits neuronaux affectés par le stress chronique ou le trauma.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) hat André Beaudry zum Unternehmensberater ernannt. Beaudry bringt über 30 Jahre Erfahrung in der Mittelbeschaffung, in den Beziehungen zur Regierung und im internationalen Programmmanagement mit und hat über 140 Millionen Dollar für verschiedene Initiativen, einschließlich der psychischen Gesundheit in mehreren Ländern, gesichert.
Als Gründer von Velocity Collaboration ist Beaudry auch Aktionär von BetterLife und wird sich darauf konzentrieren, BETR-001, die patentierte nicht-halluzinogene Verbindung des Unternehmens, voranzubringen. Das Medikament hat die meisten von der FDA geforderten IND-Studien abgeschlossen und zielt darauf ab, Angstzustände, Depressionen, PTSD, Sucht, chronische Migräne und Clusterkopfschmerzen zu behandeln, indem es die von chronischem Stress oder Trauma betroffenen neuronalen Schaltkreise erneuert.
- Appointment of experienced advisor with proven $140M+ fundraising track record
- BETR-001 has completed majority of FDA required IND-enabling studies
- New advisor is already a shareholder, showing confidence in company
- Product still pending human clinical trials
- No immediate revenue generation from core product
VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.
Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, government and philanthropic leaders to secure over
Mr. Beaudry commented, “I’m an ardent supporter and shareholder of BetterLife, and having worked with many PhD’s, I have great respect for their scientists and academic advisors. In only 4 years they’ve developed and extensively tested their patented non-hallucinogenic compound (BETR-001), which has been proven to renew the neural circuits of the brain when affected by chronic stress or trauma. I’m looking forward to collaborating with management and board to bring BETR-001 to human clinical trials. The motivation is to help millions of people, globally, lead healthier lives, now that it has successfully and safely completed the majority of its FDA required IND-enabling studies. I believe we’re just at the beginning of seeing the potential of this therapy as a safe, accessible, and patient-friendly solution to address key challenges in life - anxiety, depression, PTSD, addiction, chronic migraine and cluster headaches.”
“We are delighted to welcome André Beaudry to the BetterLife team. Mr. Beaudry’s extensive background in a variety of fundraising spaces will be very beneficial as we execute our plans to bring to market a patient-friendly non-hallucinogenic medicinal solution to address a variety of psychiatric and neurological disorders. We look forward to working with André and his network”, commented Ahmad Doroudian, CEO of BetterLife.
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.
BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.
BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.
For further information, please visit BetterLife Pharma.
Contact
David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928
Cautionary Note Regarding Forward-Looking Statements
No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
FAQ
What is BetterLife's BETR-001 compound designed to treat?
What stage of development is BETRF's BETR-001 compound currently in?
Who is the new Corporate Advisor for BETRF and what experience does he bring?
What distinguishes BETRF's BETR-001 from other similar treatments?
